Loading patent…
AssigneeUniversity of Zurich
InventorsUwe Zangemeister-Wittke, Claudio Di Paolo, Dominique Christine Tschudi, Nicholas Ronald Glover, Dimitri Peter Fitsialos
Estimating the term…
The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using VB4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.
1-57. (canceled)
A method of treating head and neck squamous cell carcinoma or bladder cancer comprising administering, directly to the cancer site, an effective amount of an immunotoxin to an animal in need thereof, wherein said immunotoxin is VB4-845 having comprising the sequence shown in SEQ ID NO:2.
The method according to claim 1 wherein the immunotoxin is VB4-845 having consisting of the sequence shown in SEQ ID NO:2.
A kit for treating head and neck squamous cell carcinoma or bladder cancer comprising an effective amount of an immunotoxin wherein the immunotoxin is VB4-845 having the sequence shown in SEQ ID NO:2 and directions for the use thereof to treat the cancer.
A method for treating head and neck squamous cell carcinoma or bladder cancer comprising:
Dependencies are inferred from the claim text.